---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-233019"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T19:58:15.347316+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma President & COO Swisher to retire; CFO Galá promoted to COO; interim CFO named

## Summary
- Daniel Swisher Jr., President & COO, to retire effective Mar 31, 2024; duties cease Oct 1, 2023.
- Renée Galá, former EVP & CFO, appointed President & COO effective Oct 1, 2023.
- Galá's base salary raised to $800K (from $735K), target bonus 75% (from 60%), plus $200K one-time equity.
- Patricia Carr, SVP & Chief Accounting Officer, named interim principal financial officer while CFO search underway.

## SEC filing metadata
- accession: 0001193125-23-233019
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/0001193125-23-233019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/d539884d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-233019
- JSON: https://secwatch.observer/filing/0001193125-23-233019.json
- Plain text: https://secwatch.observer/filing/0001193125-23-233019.txt

## Key facts
- Executive change
  Patricia Carr was appointed as principal financial officer (interim) at Jazz Pharmaceuticals plc.
  - Action: will serve as
  - Role: principal financial officer (interim)
  source text: Effective as of October 1, 2023, Patricia Carr, the Company’s Senior Vice President and Chief Accounting Officer, will serve as the Company’s principal financial officer on an interim basis while the Company conducts a search for Ms. Galá’s replacement as the Company’s Executive Vice President and Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/0001193125-23-233019-index.htm
- Executive change
  Daniel Swisher, Jr. departed as President and Chief Operating Officer at Jazz Pharmaceuticals plc.
  - Action: resign
  - Role: President and Chief Operating Officer
  source text: Mr. Swisher will cease performing the duties and responsibilities of the Company’s President and Chief Operating Officer and will resign from any office or directorship at any affiliated entity of the Company, effective October 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/0001193125-23-233019-index.htm
- Executive change
  Renée Galá was appointed as President and Chief Operating Officer at Jazz Pharmaceuticals plc.
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: On September 11, 2023, the Board appointed Renée Galá as the Company’s President and Chief Operating Officer, effective as of October 1, 2023, to succeed Mr. Swisher as the Company’s President and Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312523233019/0001193125-23-233019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.